Literature DB >> 23493202

Irreversible electroporation in porcine liver: acute computed tomography appearance of ablation zone with histopathologic correlation.

Young Joon Lee1, David S K Lu, Ferdnand Osuagwu, Charles Lassman.   

Abstract

OBJECTIVE: The objective of this study was to define acute computed tomography (CT) characteristics of ablation zone created by irreversible electroporation (IRE) in porcine liver, with histopathologic correlation.
METHODS: Twenty-three IRE ablation zones were created in 4 Yorkshire pig livers percutaneously under image guidance. A prototype generator was used (Ethicon Endo-surgery, Cincinnati, Ohio). Variable spacing of paired electrodes between 1 and 2.0 cm was used. Contrast-enhanced multiphasic CT scans were obtained. Pigs were killed after 5 to 6 hours for gross pathology sectioning with routine and vital histological stains. Computed tomography images were analyzed using 3-dimensional software, and ablation zone size measured on CT was correlated with pathologically determined size.
RESULTS: Nineteen of 19 ablation zones created with up to 1.5-cm spacing showed fusion between individual ablation zones generated by each electrode. Ablation zones were isodense precontrast and hypodense to liver postcontrast, with best delineation in the portal phase. Nine of these had nondistorted circumferential margins on both CT and gross pathology suitable for correlation, and among these, size measurements on CT were closely correlated with pathologically determined ablation zone size. Most importantly, on the delayed venous phase, there is internal enhancement within the ablation zone itself, except for small perielectrode zones that remained hypodense. On histopathology, IRE ablation zones showed preserved microvasculature with congestion of sinusoids, except for small perielectrode zones where coagulative changes were suggested.
CONCLUSION: Portal phase contrast-enhanced CT scans correlate well with liver IRE ablation size and shape on histopathology.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23493202     DOI: 10.1097/RCT.0b013e31827dbf9b

Source DB:  PubMed          Journal:  J Comput Assist Tomogr        ISSN: 0363-8715            Impact factor:   1.826


  26 in total

1.  Assessment of irreversible electroporation ablation zone using Kupffer-phase contrast-enhanced ultrasound images with Sonazoid.

Authors:  Katsutoshi Sugimoto; Fuminori Moriyasu; Kobayashi Yoshiyuki; Yasuharu Imai
Journal:  J Med Ultrason (2001)       Date:  2014-05-23       Impact factor: 1.314

2.  Adverse effects of irreversible electroporation of malignant liver tumors under CT fluoroscopic guidance: a single-center experience.

Authors:  Marco Dollinger; Lukas Philipp Beyer; Michael Haimerl; Christoph Niessen; Ernst Michael Jung; Florian Zeman; Christian Stroszczynski; Philipp Wiggermann
Journal:  Diagn Interv Radiol       Date:  2015 Nov-Dec       Impact factor: 2.630

3.  A Comparative Study of Ablation Boundary Sharpness After Percutaneous Radiofrequency, Cryo-, Microwave, and Irreversible Electroporation Ablation in Normal Swine Liver and Kidneys.

Authors:  Francois H Cornelis; Jeremy C Durack; Simon Y Kimm; Thomas Wimmer; Jonathan A Coleman; Stephen B Solomon; Govindarajan Srimathveeravalli
Journal:  Cardiovasc Intervent Radiol       Date:  2017-05-17       Impact factor: 2.740

Review 4.  Irreversible electroporation and the pancreas: What we know and where we are going?

Authors:  Shamar J Young
Journal:  World J Gastrointest Surg       Date:  2015-08-27

5.  Variation of tumoral marker after radiofrequency ablation of pancreatic adenocarcinoma.

Authors:  Mirko D'Onofrio; Emilio Barbi; Roberto Girelli; Paolo Tinazzi Martini; Riccardo De Robertis; Valentina Ciaravino; Roberto Salvia; Giovanni Butturini; Isabella Frigerio; Teresa Milazzo; Stefano Crosara; Salvatore Paiella; Paolo Pederzoli; Claudio Bassi
Journal:  J Gastrointest Oncol       Date:  2016-04

6.  Irreversible electroporation of hepatocellular carcinoma: preliminary report on the diagnostic accuracy of magnetic resonance, computer tomography, and contrast-enhanced ultrasound in evaluation of the ablated area.

Authors:  Vincenza Granata; Elisabetta de Lutio di Castelguidone; Roberta Fusco; Orlando Catalano; Mauro Piccirillo; Raffaele Palaia; Francesco Izzo; Adolfo D'Errico Gallipoli; Antonella Petrillo
Journal:  Radiol Med       Date:  2015-09-07       Impact factor: 3.469

7.  Irreversible Electroporation of Malignant Hepatic Tumors--Alterations in Venous Structures at Subacute Follow-Up and Evolution at Mid-Term Follow-Up.

Authors:  Marco Dollinger; René Müller-Wille; Florian Zeman; Michael Haimerl; Christoph Niessen; Lukas P Beyer; Sven A Lang; Andreas Teufel; Christian Stroszczynski; Philipp Wiggermann
Journal:  PLoS One       Date:  2015-08-13       Impact factor: 3.240

8.  Specific CT 3D rendering of the treatment zone after Irreversible Electroporation (IRE) in a pig liver model: the "Chebyshev Center Concept" to define the maximum treatable tumor size.

Authors:  Dominik Vollherbst; Stefan Fritz; Sascha Zelzer; Miguel F Wachter; Maya B Wolf; Ulrike Stampfl; Daniel Gnutzmann; Nadine Bellemann; Anne Schmitz; Jürgen Knapp; Philippe L Pereira; Hans U Kauczor; Jens Werner; Boris A Radeleff; Christof M Sommer
Journal:  BMC Med Imaging       Date:  2014-01-10       Impact factor: 1.930

Review 9.  A Systematic Review about Imaging and Histopathological Findings for Detecting and Evaluating Electroporation Based Treatments Response.

Authors:  Vincenza Granata; Roberta Fusco; Simona Salati; Antonella Petrillo; Elio Di Bernardo; Roberta Grassi; Raffaele Palaia; Ginevra Danti; Michelearcangelo La Porta; Matteo Cadossi; Gorana Gašljević; Gregor Sersa; Francesco Izzo
Journal:  Int J Environ Res Public Health       Date:  2021-05-24       Impact factor: 3.390

10.  Colorectal liver metastatic disease: efficacy of irreversible electroporation--a single-arm phase II clinical trial (COLDFIRE-2 trial).

Authors:  Hester J Scheffer; Laurien G P H Vroomen; Karin Nielsen; Aukje A J M van Tilborg; Emile F I Comans; Cornelis van Kuijk; Bram B van der Meijs; Janneke van den Bergh; Petrousjka M P van den Tol; Martijn R Meijerink
Journal:  BMC Cancer       Date:  2015-10-24       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.